APPENDIX
(Pending Claims, Not Amended)

1. A pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.

2. A pharmaceutical formulation according to Claim 1 comprising a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof for eliciting an analgesic or anesthetic response in a mammal.

3. A pharmaceutical formulation according to Claim 1, further comprising morphine or pharmaceutical acceptable salt thereof in combination with a nasal delivery system.

4. A pharmaceutical formulation according to Claim 3, wherein morphine or pharmaceutically acceptable salt thereof is dispersed in an aqueous or non-aqueous formulation.

5. A pharmaceutical formulation according to Claim 4, wherein morphine or pharmaceutically acceptable salt thereof is at a concentration below about 5O% w/w.

6. A pharmaceutical formulation according to Claim 4, wherein morphine or pharmaceutically acceptable salt thereof is at a concentration below about 10% w/w.

7. A pharmaceutical formulation according to Claim 4, wherein morphine or pharmaceutically acceptable salt thereof is dispersed in suspensions, solutions, powders, gels, ointments and creams.

8. A pharmaceutical formulation according to Claim 3, wherein the nasal delivery system comprises a buffer to maintain the pH of the morphine or pharmaceutically acceptable salt thereof, a thickening agent, a humectant, an absorption enhancer and combinations thereof.

9. A pharmaceutical formulation according to Claim 8 further comprising one or more pharmaceutical excipients.

10. A pharmaceutical formulation according to Claim 8 further comprising a preservative.

11. A pharmaceutical formulation according to Claim 8, wherein the buffer is selected from the group consisting of acetate, citrate, prolamine, carbonate, phosphate and combinations thereof.

12. A pharmaceutical formulation according to Claim 8, wherein the thickening agent is selected from the group consisting of methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, polyvinyl alcohol, alginates, acacia, chitosan and combinations thereof.

13. A pharmaceutical formulation according to Claim 8, wherein the humectant is selected from the group consisting of sorbitol, glycerol, mineral oil, vegetable oil and combinations thereof.

14. A pharmaceutical formulation according to Claim 8, wherein the absorption enhancer is selected from the group consisting of sodium lauryl sulfate, sodium salicylate, oleic acid, lecithin, dehydrated alcohol, Tween, Span, polyoxyl 40 stearate, polyoxy ethylene 50 stearate, edetate disodium, propylene glycol, glycerol monooleate, fusieates, bile salts, octoxynol and combinations thereof.

15. A pharmaceutical formulation according to Claim 8, wherein the absorption enhancer is selected from the group of anionic, cationic and nonionic absorption enhancers and combinations thereof.

WITHDRAWN 16. A method for eliciting an analgesic or anesthetic response in a mammal comprising nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.

WITHDRAWN 17. A method for eliciting an analgesic or anesthetic response in a mammal comprising nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0 to the mammal in combination with a nasal delivery system.

WITHDRAWN 18. A method according to Claim 17, wherein the morphine or pharmaceutically acceptable salt thereof is dispersed in an aqueous or non-aqueous formulation.

WITHDRAWN 19. A method according to Claim 18, wherein morphine or pharmaceutically acceptable salt thereof is at a concentration below about 50% w/w.

WITHDRAWN 20. A method according to Claim 18, wherein morphine or pharmaceutically acceptable salt thereof is at a concentration below about 10% w/w.

WITHDRAWN 21. A method according to Claim 18, wherein morphine or pharmaceutically acceptable salt thereof is dispersed in suspensions, solutions, powders, gels, ointments and creams.

WITHDRAWN 22. A method according to Claim 17, wherein the nasal delivery system comprises a buffer to maintain the pH of the morphine or pharmaceutically acceptable salt thereof, a thickening agent, a humectant, an absorption enhancer and combinations thereof.

WITHDRAWN 23. A method according to Claim 22 further comprising one or more pharmaceutical excipients.

WITHDRAWN 24. A method according to Claim 22 further comprising a pharmaceutically acceptable preservative.

WITHDRAWN 25. A method according to Claim 22, wherein the buffer is selected from the group consisting of acetate, citrate, prolamine, carbonate and phosphate and combinations thereof.

WITHDRAWN 26. A method according to Claim 22, wherein the thickening agent is selected from the group consisting of methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, polyvinyl alcohol, alginates, acacia, chitosan and combinations thereof.

WITHDRAWN 27. A method according to Claim 22, wherein the humectant is selected from the group consisting of sorbitol, glycerol, mineral oil, vegetable oil and combinations thereof.

WITHDRAWN 28. A method according to Claim 22, wherein the absorption enhancer is selected from the group consisting of sodium lauryl sulfate, sodium salicylate, oleic acid, lecithin, dehydrated alcohol, Tween, Span, polyoxyl 40 stearate, polyoxyethylene 50 stearate, edetate disodium, propylene glycol, glycerol, monooleate, fusieates, bile salts, octoxynol and combinations thereof.

WITHDRAWN 29. A method according to Claim 22, wherein the absorption enhancer is selected from the group of anionic, cationic and nonionic surfactants and combinations thereof.

30. A pharmaceutical formulation, according to Claim 1, for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH of 3.5.

31. A pharmaceutical formulation according, to Claim 1, for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH of 4.0.

32. A pharmaceutical formulation according to Claim 1, for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 5.0 to about 6.0.